SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) – Investment analysts at Wedbush decreased their FY2027 earnings per share estimates for shares of SpringWorks Therapeutics in a report released on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $3.42 per share for the year, down from their previous estimate of $3.47. Wedbush currently has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.12) per share.
Other equities research analysts also recently issued reports about the company. Guggenheim decreased their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. HC Wainwright lowered their price objective on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research report on Tuesday, November 12th. Finally, Evercore ISI began coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and a consensus target price of $70.00.
SpringWorks Therapeutics Price Performance
NASDAQ SWTX opened at $32.50 on Wednesday. The company’s fifty day moving average is $37.97 and its two-hundred day moving average is $36.40. SpringWorks Therapeutics has a 52-week low of $28.21 and a 52-week high of $53.92. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of -8.38 and a beta of 0.82.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The company had revenue of $49.10 million during the quarter, compared to analysts’ expectations of $53.28 million. During the same period in the prior year, the business earned ($1.27) earnings per share. SpringWorks Therapeutics’s revenue for the quarter was up 4810.0% compared to the same quarter last year.
Hedge Funds Weigh In On SpringWorks Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SWTX. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after buying an additional 474 shares in the last quarter. Quantbot Technologies LP bought a new position in SpringWorks Therapeutics in the 3rd quarter valued at $147,000. Quarry LP boosted its stake in SpringWorks Therapeutics by 56.3% in the second quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after purchasing an additional 1,800 shares in the last quarter. Park Avenue Securities LLC acquired a new stake in shares of SpringWorks Therapeutics in the fourth quarter valued at $203,000. Finally, Commerce Bank bought a new position in shares of SpringWorks Therapeutics in the third quarter valued at about $207,000.
Insiders Place Their Bets
In other news, COO Badreddin Edris sold 20,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total value of $839,400.00. Following the sale, the chief operating officer now owns 209,600 shares of the company’s stock, valued at approximately $8,796,912. This represents a 8.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.61% of the company’s stock.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Further Reading
- Five stocks we like better than SpringWorks Therapeutics
- Where to Find Earnings Call Transcripts
- Carnival: 4 Reasons to Set Sail in This Stock in 2025
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- AAR Corp Jets Higher on Robust Demand for Aircraft Components
- Profitably Trade Stocks at 52-Week Highs
- Everything You Need to Know About Palantir’s Stock Slide
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.